RESULTS: Of 43 patients identified, 25 patients were included in the study. Of those 10 (40%) were female, with a mean age of 62.7 years (range 30-92). Median ECOG performance status (PS) was 3; 23 (92%) patients had poor PS. Median body-mass index (BMI) was 25.5 and average albumin was 2.6g/dl (lower reference limit 3.6). All patients had moderate to large sized pleural effusion on chest imaging and 21 (84%) had dyspnea requiring supplementary oxygen, with median respiratory rate of 24 breaths/min and median heart rate 105 beats/minute. 9 patients had lung cancer, 7 had breast cancer, 4 had gastrointestinal cancer, 2 had lymphoma, 2 had genitourinary malignancy, and 1 had melanoma. In 20 of the patients the TIPC was placed after initial small-bore catheter thoracostomy, as per institutional protocol. 17 (68%) patients received Aspira TIPC and 8 (32%) patients received PleurX TIPC. Both groups of patients had similar characteristics. Symptom relief was similar in both groups. Median LOS was 9 days in Aspira group (AG), and 13 days in PleurX group (PG). 7 patients in AG developed catheter-related complications such as infection at catheter site (2) or catheter malfunction (5), while 2 patients in PG had catheter infection or malfunction. In the post-TIPC placement period the median chest X-ray count was 1 in AG and 2.5 in PG. 4 patients died in the AG group and 3 in the PG.